182 related articles for article (PubMed ID: 31879191)
1. Rapid Clinical and Radiologic Responses With Larotrectinib Treatment in a Patient With TRK-Fusion-Positive Metastatic Lung Cancer.
Hochmair MJ; Setinek U; Krenbek D; Fazekas A; Illini O; Weinlinger C; Draxler H; Marcher M; Valipour A; Müllauer L; Beer L
Clin Lung Cancer; 2020 Mar; 21(2):e49-e53. PubMed ID: 31879191
[No Abstract] [Full Text] [Related]
2. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.
DuBois SG; Laetsch TW; Federman N; Turpin BK; Albert CM; Nagasubramanian R; Anderson ME; Davis JL; Qamoos HE; Reynolds ME; Cruickshank S; Cox MC; Hawkins DS; Mascarenhas L; Pappo AS
Cancer; 2018 Nov; 124(21):4241-4247. PubMed ID: 30204247
[TBL] [Abstract][Full Text] [Related]
3. Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers.
Farago AF; Demetri GD
Future Oncol; 2020 Mar; 16(9):417-425. PubMed ID: 32129093
[TBL] [Abstract][Full Text] [Related]
4. A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib.
Caldwell KJ; De La Cuesta E; Morin C; Pappo A; Helmig S
Pediatr Blood Cancer; 2020 Sep; 67(9):e28330. PubMed ID: 32452122
[TBL] [Abstract][Full Text] [Related]
5. A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report.
Zhang L; Liu H; Tian Y; Wang H; Yang X
BMC Pulm Med; 2021 Apr; 21(1):125. PubMed ID: 33865348
[TBL] [Abstract][Full Text] [Related]
6. The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer.
Roth JA; Carlson JJ; Xia F; Williamson T; Sullivan SD
J Manag Care Spec Pharm; 2020 Aug; 26(8):981-986. PubMed ID: 32329651
[TBL] [Abstract][Full Text] [Related]
7. Testing algorithm for identification of patients with TRK fusion cancer.
Penault-Llorca F; Rudzinski ER; Sepulveda AR
J Clin Pathol; 2019 Jul; 72(7):460-467. PubMed ID: 31072837
[TBL] [Abstract][Full Text] [Related]
8. Improving outcomes in pediatric NTRK gene fusion-positive solid tumors: importance of genomic testing and targeted therapy with the TRK inhibitor larotrectinib.
Laetsch TW
Clin Adv Hematol Oncol; 2024 May; 22 Suppl 3(4):1-11. PubMed ID: 38739704
[No Abstract] [Full Text] [Related]
9. Tropomyosin receptor kinase inhibitors in the management of sarcomas.
Wilding CP; Loong HH; Huang PH; Jones RL
Curr Opin Oncol; 2020 Jul; 32(4):307-313. PubMed ID: 32541318
[TBL] [Abstract][Full Text] [Related]
10. Larotrectinib followed by selitrectinib in a novel
Goh XN; Seng MS; Loh AHP; Gupta A; Chang KTE; Iyer P
J Oncol Pharm Pract; 2021 Mar; 27(2):485-489. PubMed ID: 32693686
[TBL] [Abstract][Full Text] [Related]
11. Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas.
Kummar S; Shen L; Hong DS; McDermott R; Keedy VL; Casanova M; Demetri GD; Dowlati A; Melcón SG; Lassen UN; Leyvraz S; Liu T; Moreno V; Patel J; Patil T; Mallick AB; Sousa N; Tahara M; Ziegler DS; Norenberg R; Arvis P; Brega N; Drilon A; Tan DSW
Cancer; 2023 Dec; 129(23):3772-3782. PubMed ID: 37769113
[TBL] [Abstract][Full Text] [Related]
12. Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion.
O'Reilly EM; Hechtman JF
Ann Oncol; 2019 Nov; 30(Suppl_8):viii36-viii40. PubMed ID: 31605106
[TBL] [Abstract][Full Text] [Related]
13. Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
Yang JCH; Brose MS; Castro G; Kim ES; Lassen UN; Leyvraz S; Pappo A; López-Ríos F; Reeves JA; Fellous M; Penault-Llorca F; Rudzinski ER; Tabatabai G; Vassal G; Drilon A; Trent J
BMC Cancer; 2022 Jun; 22(1):625. PubMed ID: 35672677
[TBL] [Abstract][Full Text] [Related]
14. NTRK fusion-positive cancers and TRK inhibitor therapy.
Cocco E; Scaltriti M; Drilon A
Nat Rev Clin Oncol; 2018 Dec; 15(12):731-747. PubMed ID: 30333516
[TBL] [Abstract][Full Text] [Related]
15. TRK inhibitors in TRK fusion-positive cancers.
Drilon A
Ann Oncol; 2019 Nov; 30 Suppl 8():viii23-viii30. PubMed ID: 32223935
[TBL] [Abstract][Full Text] [Related]
16. Larotrectinib in NTRK-Rearranged Solid Tumors
Wilson FH; Herbst RS
Biochemistry; 2019 Mar; 58(12):1555-1557. PubMed ID: 30865435
[No Abstract] [Full Text] [Related]
17. [Drug approval : entrectinib and larotrectinib - cancers with NTRK fusion].
Delaye M; Rodrigues M
Bull Cancer; 2020 Nov; 107(11):1085-1086. PubMed ID: 33169692
[No Abstract] [Full Text] [Related]
18. Loxo TRK inhibitor data wows oncologists.
Dolgin E
Nat Biotechnol; 2017 Aug; 35(8):694-695. PubMed ID: 28787403
[No Abstract] [Full Text] [Related]
19. Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib.
Kummar S; Berlin J; Mascarenhas L; van Tilburg CM; Geoerger B; Lassen UN; Schilder RJ; Turpin B; Nanda S; Keating K; Childs BH; Chirila C; Laetsch TW; Hyman DM; Drilon A; Hong DS
Curr Probl Cancer; 2021 Dec; 45(6):100734. PubMed ID: 33865615
[TBL] [Abstract][Full Text] [Related]
20. [NTRK Fusions: A new way of treatment for gastro-intestinal tumor?].
Ouali K; Pellat A; Cohen R; Svrcek M; Penault-Llorca F; André T
Bull Cancer; 2020 Apr; 107(4):447-457. PubMed ID: 32067719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
